In this regard, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomized trial on the role of IL-1β inhibition in atherosclerosis, secondarily aimed at establishing whether low (50 mg), medium (150 mg), or high (300 mg)-dose canakinumab given sc every three months might alter cancer incidence [44,45]. This evidence concerns the gene IL1B and deep vein thrombosis.